Korean Journal of Veterinary Service (한국동물위생학회지)

The Korean Society of Veterinary Service (한국동물위생학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of ST2 and NT-proBNP as cardiac biomarkers in dogs with heartworm disease

  • Lee, Kiho (College of Veterinary Medicine, Chungnam National University) ;
  • Park, Jun-Seok (College of Veterinary Medicine, Chungnam National University) ;
  • Seo, Kyoung-Won (College of Veterinary Medicine, Chungnam National University) ;
  • Song, Kun-Ho (College of Veterinary Medicine, Chungnam National University)
  • Received : 2018.01.23
  • Accepted : 2017.04.10
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

This study compared serum concentrations of suppression of tumorigenicity 2 (ST2) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) between healthy and heartworm- infected dogs. Eighteen heartworm-infected dogs and five healthy dogs were included in the study. Dogs were diagnosed and categorized by history, clinical signs, and blood assay, thoracic radiography, echocardiography, and commercial ELISA kit results. Serum samples were sent to the IDEXX reference laboratory for NT-proBNP measurement. ST2 was examined by using a canine interleukin 33 receptor ELISA kit with the quantitative sandwich ELISA method. The severely infected group showed significant elevation of NT-proBNP concentration over those of the control (P=0.03) and mildly infected (P=0.04) group. There were no significant difference in ST2 concentrations among the three groups. The usefulness of NT-proBNP as a cardiac biomarker in dogs with severe heartworm disease was confirmed by the results of this study. Further investigations to assess ST2 as a cardiac biomarker are warranted.

Keywords

References

  1. American heartworm society, 2014. Guidelines for the diagnosis, prevention and management of heartworm (Dirofilaria immitis) infection in dogs. http://www.heartwormsociety.org/images/pdf/2014-AHS-Canine-Guidelines.pdf.
  2. Atkinson AJ, Colburn WA, Degruttola VG, Demets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT, Spilker BA, Woodcock J, Zeger SL. 2001. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95. https://doi.org/10.1067/mcp.2001.113989
  3. Bayes-Genis A, Antonio M, Galan A, Sanz H, Urrutia A, Cabanes R, Cano L, Gonzalez B, Diez C, Pascual T, Elosua R, Lupon J. 2012. Combined use of high‐sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 14: 32-38. https://doi.org/10.1093/eurjhf/hfr156
  4. Boswood A. 2009. Biomarkers in cardiovascular disease: Beyond natriuretic peptides. J Vet Cardiol 11: S23-S32. https://doi.org/10.1016/j.jvc.2009.01.003
  5. Braunwald E. 2008. Biomarkers in heart failure. N Engl J Med 358; 2148-2159. https://doi.org/10.1056/NEJMra0800239
  6. Carreton E, Cobera JA, Juste MC, Morchon R, Simon F, Montoya-Alonso JA. 2011. Dirofilaria immitis infection in dogs: Cardiopulmonary biomarker levels. Vet Parasitol 176: 313-316. https://doi.org/10.1016/j.vetpar.2011.01.015
  7. Carreton E, Morchon R, Simon F, Juste MC, Mendez JC, Montoya-Alonso JA. 2014. Cardiopulmonary and in- flammatory biomarkers in the assessment of the severity of canine dirofilariasis. Vet Parasitol 206: 43-47. https://doi.org/10.1016/j.vetpar.2014.08.019
  8. Di Sacco B, Vezzoni A. Clinical classification of heartworm disease for the purpose of adding objectivity to the assessment of therapeutic efficacy of adulticidal drugs in the field. 1992. In: Soll, M.D. (Ed.), Proceedings of the Heartworm Symposium'92. American Heartworm Society, Batavia, IL: 209-214.
  9. Ebisawa T, Ohta Y, Funayama M, Morita K, Uechi M. 2012. Clinical use of n-terminal pro-brain natriuretic peptide concentrations for assessing the severity and prognosis of myxomatous mitral valve disease in dogs. Intern J Appl Res Vet Med 10: 234-242.
  10. Ettinger SJ, Farace G, Forney SD, Frye M, Beardow A. 2012. Evaluation of plasma N-terminal pro-B-type natriuretic peptide concentrations in dogs with and without cardiac disease. J Am Vet Med Assoc 240: 171-180. https://doi.org/10.2460/javma.240.2.171
  11. Kelihan HB, Oyama MA, Reynolds CA, Stepien RL. 2009. Weekly variability of plasma and serum NT-proBNP measurements in normal dogs. J Vet Cardiol 11: S93-S97. https://doi.org/10.1016/j.jvc.2009.03.003
  12. Oyama MA, Fox PR, Rush JE, Rozanski EA, Lesser M. 2008. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc 232: 1496-1503. https://doi.org/10.2460/javma.232.10.1496
  13. Piper S, Sherwood R, Amin-Youssef G, McDonagh T. 2016. Biologic variability of soluble ST2 in patients with stable chronic heart failure and implications for monitoring. Am J Cardiol 118: 95-98. https://doi.org/10.1016/j.amjcard.2016.04.017
  14. Ruaux C, Scollan K, Suchodolski JS, Steiner JM, Sisson DD. 2015. Biologic variability in NT-proBNP and cardiac troponin-I in healthy dogs and dogs with mitral valve degeneration. Vet Clin Pathol 44: 420-430. https://doi.org/10.1111/vcp.12268
  15. Schmidt MK, Reynolds CA, Estrada AH, Prosek R, Maisenbacher HW, Sleeper MM, Oyama MA. 2009. Effect of azotemia on serum N-terminal proBNP concentration in dogs with normal cardiac function: a pilot study. J Vet Cardiol 11: S81-S86. https://doi.org/10.1016/j.jvc.2009.02.001
  16. Shah RV, Januzzi JL. 2010. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep 7: 9-14. https://doi.org/10.1007/s11897-010-0005-9
  17. Song KH, Park JE, Lee DH, Lee SH, Shin HJ. 2010. Serological update and molecular characterization of Dirofilaria im- mitis in dogs, South Korea. Res Vet Sci 88: 467-469. https://doi.org/10.1016/j.rvsc.2009.10.007
  18. Villacorta H, Maisel AS. 2016. Soluble ST2 testing: a promising biomarker in the management of heart failure. Arq Bras Cardiol 106: 145-152.